- Home
- TRIP vs DSGN Comparison
TRIP vs DSGN Comparison
Compare TRIP & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRIP | DSGN |
|---|---|---|
| Founded | 2000 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 853.8M |
| IPO Year | 2011 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TRIP | DSGN |
|---|---|---|
| Price | $9.19 | $10.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 8 |
| Target Price | $13.21 | ★ $21.71 |
| AVG Volume (30 Days) | ★ 2.8M | 458.9K |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 675.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,556,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.37 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.02 | $6.16 |
| 52 Week High | $17.53 | $17.25 |
Technical Indicators
Market Signals| Indicator | TRIP | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 50.90 | 41.75 |
| Support Level | $9.03 | $9.78 |
| Resistance Level | $9.72 | $11.44 |
| Average True Range (ATR) | 0.33 | 0.65 |
| MACD | 0.02 | 0.13 |
| Stochastic Oscillator | 49.29 | 56.05 |
Price Performance
Historical ComparisonAbout TRIP TripAdvisor Inc.
Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on several million accommodations, experiences, airlines, and cruises. In 2025, 42% of revenue came from the company's core Hotel and Other segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 46% of revenue in 2025. The company is selling TheFork, its dining brand, which represented 12% of sales.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.